Loading...
In December 2025, the U.S. Food and Drug Administration approved two new oral treatments for uncomplicated urogenital gonorrhea:
Gepotidacin, an inhibitor of bacterial topoisomerase enzymes, that was also recently approved for the treatment of uncomplicated urinary tract infections (UTIs)
Zoliflodacin, a first-in-class antibiotic that inhibits bacterial DNA gyrase
Gonorrhea in the United States is currently treated with a single 500-mg dose of intramuscular ceftriaxone. Although this regimen remains effective in the United States, oral treatment would be preferable, and novel antibiotics are needed in settings with higher rates of ceftriaxone resistance. Both gepotidacin and zoliflodacin are active in vitro against strains of Neisseria …
